OR WAIT null SECS
April 18, 2023
Merck will acquire Prometheus Biosciences, a clinical-stage biotechnology company specializing in immune-mediated diseases, at a total equity valuation of $10.8 billion.
April 05, 2023
Sartorius’ acquisition of Polyplus is designed to strengthen its cell and gene therapy capabilities.
March 30, 2023
The Supreme Court heard oral arguments concerning the legitimacy of “genus clauses” in bio/pharma patents.
March 29, 2023
Narcan, from Emergent Solutions, will be the first naloxone product permitted for use without prescription by FDA.
March 16, 2023
Pfizer will acquire all outstanding shares of Seagen for a total of $43 billion.
March 14, 2023
Sumitovant Bipharma has completed its acquisition of Myovant Sciences for approximately $1.7 billion.
March 13, 2023
Silicon Valley Bank has collapsed, leaving many biotechnology companies unsure of the future.
March 02, 2023
Lilly will cap insulin prices for patients with and without insurance at $35 per month.
February 28, 2023
Moderna and Merck’s investigational personalized mRNA cancer vaccine has been granted Breakthrough Therapy Designation by FDA.
February 22, 2023
Pfizer reports that the combination of talazoparib and enzalutamide demonstrated statistically significant improvement in patient survival in a Phase III trial.